In a filing, RAPT Therapeutics Inc. revealed its Chief Medical Officer HO WILLIAM unloaded Company’s shares for reported $47300.0 on Aug 18. In the deal valued at $18.92 per share,2,500 shares were sold. As a result of this transaction, HO WILLIAM now holds 21,289 shares worth roughly $ 0.43 million.
Then, HO WILLIAM sold 5,000 shares, generating $94,400 in total proceeds. Upon selling the shares at $18.88, the Chief Medical Officer now owns 20,992 shares.
Before that, Robbins Wendye bought 2,500 shares. RAPT Therapeutics Inc. shares valued at $50,125 were divested by the Director at a price of $20.05 per share. As a result of the transaction, Robbins Wendye now holds 6,500 shares, worth roughly $0.13 million.
Stifel initiated its RAPT Therapeutics Inc. [RAPT] rating to a Buy in a research note published on Friday, August 09, 2023; the price target was $40. PT values the company’s stock at a premium of 49.62 to its Friday closing price.
Price Performance Review of RAPT
On Friday, RAPT Therapeutics Inc. [NASDAQ:RAPT] saw its stock jump 5.50% to $20.15. On the same session, the stock had its day’s lowest price of $19.30, but rose to a high of $20.20. Over the last five days, the stock has gained 6.11%. RAPT Therapeutics Inc. shares have risen nearly 1.77% since the year began. Nevertheless, the stocks have fallen -24.56% over the past one year. While a 52-week high of $31.45 was reached on 03/03/23, a 52-week low of $15.59 was recorded on 04/10/23. SMA at 50 days reached $21.06, while 200 days put it at $21.45. A total of 0.18 million shares were traded, compared to the trading of 0.24 million shares in the previous session.
Levels Of Support And Resistance For RAPT Stock
The 24-hour chart illustrates a support level at 19.57, which if violated will result in even more drops to 18.98. On the upside, there is a resistance level at 20.47. A further resistance level may holdings at 20.78. The Relative Strength Index (RSI) on the 14-day chart is 47.59, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.03, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 61.50%. Stochastics %K at 23.07% indicates the stock is a holding.
How much short interest is there in RAPT Therapeutics Inc.?
A steep rise in short interest was recorded in RAPT Therapeutics Inc. stocks on Aug 14, 2023, growing by 70000.0 shares to a total of 3.97 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 3.9 million shares. There was a rise of 1.76%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 15.66% of the overall stock float, the days-to-cover ratio (short ratio) rose to 14.98.
RAPT Therapeutics Inc. [RAPT] – Who Are The Largest Shareholders?
In filings from Fidelity Management & Research Co, it is revealed that the company now owns 3,485,663 shares, or roughly 10.15% of the outstanding RAPT shares. In other words, the investor’s shares have risen by 598,963 from its previous 13-F filing of 2886700.0. Additionally, T. Rowe Price Associates, Inc. increased 4.48% of its stake after which the total value it holdings stand at $81,914,167, while Perceptive Advisors LLC reduced -0.14% of its stake to hold $54.69 million in the firm. Over the last quarter, BlackRock Fund Advisors purchased 13,508 shares of RAPT Therapeutics Inc., while The Vanguard Group, Inc. bought 363,576 shares. At present, SSgA Funds Management, Inc. is holding 1,702,045 shares valued at $40.68 million. Great Point Partners LLC owned 1,465,151 shares of the company at the time of its most recent 13F filing, worth $35.02 million.
According to FactSet, RAPT Therapeutics Inc.’s share price will average $38.60 in the next year, based on opinions of analysts polled by the firm. This is up nearly 112.04 percent from its previous closing price of $19.10. Analysts expect RAPT Therapeutics Inc. stock to reach the higher price of $48.00, while the lowest price estimate is $21.00. However, 10 analysts have rated RAPT stock as a Buy in their predictions for 2023.